 AtriCure, Inc. Nasdaq: ATRC, a leading innovator in treatments for atrial fibrillation Afib and left atrial appendage LAA management, today announced the results from the CONVERGE IDE clinical trial. This first-of-its-kind trial, designed to demonstrate superiority, showed an 18 difference in favor of the hybrid Convergent procedure as compared to endocardial catheter ablation alone. The results of the trial were presented as part of the late-breaking clinical trials at the Heart Rhythm Societys HRS Annual Scientific Session and were broadcasted virtually via the Heart Rhythm 365 digital platform. 